Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$11.35 - $16.73 $13,790 - $20,326
1,215 Added 5.15%
24,806 $365,000
Q4 2023

Feb 13, 2024

SELL
$5.77 - $12.19 $548 - $1,158
-95 Reduced 0.4%
23,591 $283,000
Q3 2023

Nov 13, 2023

BUY
$6.27 - $8.15 $5,279 - $6,862
842 Added 3.69%
23,686 $150,000
Q2 2023

Aug 04, 2023

SELL
$6.63 - $9.9 $1,253 - $1,871
-189 Reduced 0.82%
22,844 $179,000
Q1 2023

May 12, 2023

BUY
$5.72 - $7.91 $2,619 - $3,622
458 Added 2.03%
23,033 $159,000
Q4 2022

Feb 10, 2023

SELL
$4.68 - $6.54 $383 - $536
-82 Reduced 0.36%
22,575 $143,000
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $1,197 - $2,693
321 Added 1.44%
22,657 $123,000
Q2 2022

Aug 12, 2022

BUY
$3.37 - $7.55 $75,272 - $168,636
22,336 New
22,336 $97,000
Q2 2021

Aug 13, 2021

SELL
$2.51 - $3.11 $39,630 - $49,103
-15,789 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$2.42 - $3.6 $101 - $151
42 Added 0.27%
15,789 $42,000
Q4 2020

Feb 12, 2021

SELL
$2.6 - $5.79 $1,175 - $2,617
-452 Reduced 2.79%
15,747 $46,000
Q3 2020

Nov 04, 2020

BUY
$4.34 - $8.28 $16,257 - $31,016
3,746 Added 30.08%
16,199 $80,000
Q2 2020

Aug 12, 2020

BUY
$4.86 - $11.44 $21,904 - $51,560
4,507 Added 56.72%
12,453 $105,000
Q1 2020

May 04, 2020

SELL
$3.31 - $7.15 $1,515 - $3,274
-458 Reduced 5.45%
7,946 $37,000
Q4 2019

Feb 05, 2020

SELL
$3.07 - $5.11 $221 - $367
-72 Reduced 0.85%
8,404 $36,000
Q3 2019

Nov 08, 2019

SELL
$3.29 - $8.24 $194 - $486
-59 Reduced 0.69%
8,476 $30,000
Q2 2019

Aug 13, 2019

BUY
$7.92 - $11.39 $31,656 - $45,525
3,997 Added 88.08%
8,535 $68,000
Q1 2019

May 06, 2019

BUY
$10.82 - $21.79 $14,358 - $28,915
1,327 Added 41.33%
4,538 $52,000
Q4 2018

Feb 13, 2019

SELL
$16.38 - $37.18 $409 - $929
-25 Reduced 0.77%
3,211 $70,000
Q3 2018

Nov 09, 2018

BUY
$10.96 - $28.9 $35,466 - $93,520
3,236 New
3,236 $89,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $709M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.